Telbivudine: A review of its use in compensated chronic hepatitis B

Drugs

Volumn 70, Issue 14, 2010, Pages 1857-1883

  McKeage, Kate ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Hepatitis B; Telbivudine, general

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CYCLOSPORIN; CYTOCHROME P450; DNA POLYMERASE; DRUG BINDING PROTEIN; ENTECAVIR; HEPATITIS B ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; CARCINOGENICITY; CAUCASIAN; CHINESE; CLINICAL ASSESSMENT; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; CROSS RESISTANCE; CYTOKINE PRODUCTION; DNA SYNTHESIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; GENETIC RESISTANCE; GENOTOXICITY; HEADACHE; HEPATITIS; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; KIDNEY CLEARANCE; LIVER CELL; LIVER CIRRHOSIS; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MURINE HEPATITIS CORONAVIRUS; MYALGIA; MYOPATHY; MYOSITIS; NEURALGIA; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; POLYMYOSITIS; POLYNEUROPATHY; PRACTICE GUIDELINE; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; SENSORY DYSFUNCTION; SEROCONVERSION; SIDE EFFECT; T LYMPHOCYTE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIREMIA; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; PYRIMIDINONES;

HEPATITIS B VIRUS;

EID: 77956582171     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204330-000000000-00000     Document Type: Review

References (85)

1. World Health Organization. Hepatitis B: fact sheet [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs204/en/index.html [Accessed 2010 Mar 3]
2. Cooke GS, Main J, Thursz MR. Treatment for hepatitis B. BMJ 2010; 340: 87-91
3. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol He-patol 2000; 15: 1356-1361
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242
5. Berg T, Benhamou Y, Calleja JL, et al. A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepat 2010; 17 (9): 624-630
6. Akuta N, Kumada H. Influence of hepatitis B virus geno-types on the response to antiviral therapies. J Antimicrob Chemother 2005; 55: 139-142
7. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009 Sep; 50 (3): 661-662
8. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006; 11 (6): 669-679
9. Liaw Y-F. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009; 3: 425-433
10. Liaw YF, Lau GK, Kao JH, et al. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. Epub 2010 Mar 18
11. Liaw Y-F, Leung N, Kao J-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283
12. Keam SJ. Telbivudine. Drugs 2007; 67 (13): 1917-1929
13. European Medicines Agency. Sebivo® 600 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/docs//en-GB/document-library/EPAR-Product-Information/ human/000713/WC5000049337.pdf [Accessed 2010 May 21]
14. Novartis Pharmaceuticals Corporation. Tyzeka® (telbivu-dine) tablets and oral solution. US prescribing information [online]. Available from URL: http://www.pharma.us. novartis.com/product/pi/pdf/tyzeka.pdf [Accessed 2010 May 12]
15. Jarvis B, Faulds D. Lamivudine: a review of its therapeu-tic potential in chronic hepatitis B [published erratum appears in Drugs 1999; 58: 587]. Drugs 1999 Jul; 58 (1): 101-141
16. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63 (20): 2215-2234
17. Perry C, Simpson D. Tenofovir disoproxil fumarate: in chronic hepatitis B. Drugs 2009; 69 (16): 2245-2256
18. Scott LJ, Keating GM. Entecavir: a review of its use in chronic hepatitis B. Drugs 2009; 69 (8): 1003-1033
19. Avila C, Karwowska S, Lai C-H. Telbivudine shows no ac-tivity against 8 different clinical HIV isolates and 2 multidrug resisatnt HIV isolates [abstract no. 551]. J Hepatol 2009; 50 Suppl.1: S204.
20. Plus poster presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL); 2009 Apr 22-26; Copenhagen
21. Lin K, Karwowska S, Lam E, et al. Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. Antimicrob Agents Chemother 2010; 54 (6): 2670-2673
22. Delaney WEIV, Yang H, Miller MD, et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004 Oct; 48 (10): 3702-3710
23. Zhu Y, Curtis M, Qi X, et al. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother 2009; 19 (4): 165-176
24. Patty A, Li B, Serra I, et al. In vitro anti-HBV activity of telbivudine/tenofovir and telbivudine/entecavir combinations [abstract no. 958]. Hepatology 2007 Oct; 46 (4 Suppl. 1): 663
25. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivu-dine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005 Aug; 129 (2): 528-536
26. Lai CL, Leung NW, Teo EK, et al. Phase IIb extended-treatment trial of telbivudine vs lamivudine vs combination treatment in hepatitis B patients: two-year results [abstract no. 320]. Gastroenterology 2005 Apr; 128 (4 Suppl. 2): 692
27. Suh DJ, Um SH, Herrmann E, et al. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study in patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother 2010 Mar; 54 (3): 1242-1247
28. Seifer M, Patty A, Serra I, et al. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res 2009 Feb; 81 (2): 147-155
29. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10 (5): 625-633
30. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial re-sults: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009 Feb; 136 (2): 486-495
31. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lami-vudine in patients with chronic hepatitis B. N Engl J Med 2007 Dec 20; 357 (25): 2576-2588
32. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008 Feb; 47 (2): 447-454
33. Safadi R, Xie Q, Chen Y, et al. The efficacy of switching to telbivudine (LTD) in chronic hepatitis B (CHB) patients previously treated with lamivudine (LAM) [abstract no. PE158 plus poster]. 19th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2009 Feb 13-16; Hong Kong
34. Hsu CW, Chen YC, Liaw YF, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients [abstract plus poster no. 911]. 44th Annual Meeting of the European Association for the Study of the Liver (EASL); 2009 Apr 22-26; Copenhagen
35. Jia J-D, Gane E, Wang Y, et al. Prolonged efficacy and safety of 4 years continuous telbivudine treatment in chronic hepatitis B (CHB) patients from GLOBE and 015 studies [abstract plus poster]. 20th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2010 Mar 25-28; Beijing
36. Wu ZG, Yan WM, Guo W, et al. Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis. J Viral Hepat 2010; 17 Suppl. 1: 24-33
37. Evans A, Riva A, Cooksley H, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatol-ogy 2008; 48: 759-769
38. Zhang L, Chen M, Zhang DZ, et al. The dynamic change of Th1/Th2 type cytokines in peripheral blood and its clinical significance in the hepatitis B e antigen positive patients treated with telbivudine [abstract no. PE200]. Hepatol Int 2009; 3: 136
39. Fisicaro P, Valdatta C, Massari M, et al. Anti-viral in-trahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010 Feb; 138 (2): 682-693
40. Peng G, Li S, Wu W, et al. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008 Feb; 45 (4): 963-970
41. Xie Z, Chen Y, Zhao S, et al. Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest 2009; 38 (7): 624-638
42. Zhou XJ, Lloyd DM, Chao GC, et al. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol 2006 Mar; 46 (3): 275-281
43. Dong M, Persohn E, Grenet O, et al. Absence of mi-tochondrial toxicity of telbivudine in skeletal muscle cells, hepatocytes, and neuronal cells from rat or human [abstract plus poster]. 48th Annual Meeting of the Society of Toxicology; 2009 Mar 15-19; Baltimore (MD)
44. Bridges EG, Selden JR, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother 2008 Jul; 52 (7): 2521-2528
45. Poordad F, Zeldin G, Harris SI, et al. Absence of effect of telbivudine on cardiac repolarization: results of a thorough QT/QTc study in healthy participants. J Clin Pharmacol 2009 Dec; 49 (12): 1436-1446
46. International Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs [online]. Available from URL http://www.fda.gov/down loads/RegulatoryInformation/Guidances/ucm129357.pdf [Accessed 2010 Jun 3]
47. Hu P, Jiang J, Wang H, et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J Clin Pharmacol 2006 Sep; 46 (9): 999-1007
48. Zhou XJ, Fielman BA, Lloyd DM, et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Anti-microb Agents Chemother 2006; 50 (7): 2309-2315
49. Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004 Sep; 40 (3): 719-726
50. Zhou XJ, Lim SG, Lloyd DM, et al. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Anti-microb Agents Chemother 2006 Mar; 50 (3): 874-879
51. Zhou XJ, Marbury TC, Alcorn HW, et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother 2006 May; 50 (5): 1721-1726
52. Zhou XJ, Swan S, Smith WB, et al. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 2007 Dec; 51 (12): 4231-4235
53. Zhou XJ, Ke J, Sallas WM, et al. Population pharmaco-kinetics of telbivudine and determination of dose adjustment for patients with renal impairment. J Clin Pharmacol 2009 Jun; 49 (6): 725-734
54. Wang Y, Jia J, Hou J, et al. A phase III comparative trial of telbivudine vs lamivudine in Chinese patients with chronic hepatitis B: two-year results [abstract no. S1768]. Digestive Disease Week; 2007 May 19-24; Washington, DC
55. Chen YC, Hsu CW, Liaw YF, et al. Efficacy of 3 years of telbivudine treatment for patients with genotype B/C chronic hepatitis B [abstract no. 349 plus poster]. 44th Annual Meeting of the European Association for the Study of the Liver (EASL); 2009 Apr 22-26; Copenhagen
56. Jia J-D, Hou J-L, Yin Y-K, et al. Prolonged efficacy and safety of 3 years' continuous telbivudine treatment in Chinese chronic hepatitis B patients [abstract plus poster]. 19th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2009 Feb 13-16; Hong Kong
57. Ren H, Wang Y, Thongsawat S, et al. Telbivudine-induced HBeAg seroconversion in chronic hepatitis B (CHB) patients is durable during 2 years off-treatment follow-up [poster no.190]. 20th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2010 Mar 25-28; Beijing
58. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009 Jul; 51 (1): 11-20
59. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbi-vudine or adefovir: a randomized trial. Ann Intern Med 2007 Dec 4; 147 (11): 745-754
60. Zheng M-H, Shi K-Q, Dai Z-J, et al. A 24-week, parallell-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of HBeAg-positive chronic hepatitis B [abstract]. 45th Annual Meeting of the European Association for the Study of the Liver (EASL); 2010 Apr 14-18; Vienna
61. Liang J, Han T, Xiao SX. Telbivudine treatment on cirrhosis resulting from chronic hepatitis B [in Chinese]. Chin J He-patol 2009 Jan; 17 (1): 24-27
62. Moon YM, Hwang SG, Kim BS, et al. The efficacy and safety of telbivudine in Korean patients with chronic hepatitis B [in Korean]. Korean J Hepatol 2007 Dec; 13 (4): 503-512
63. O'Brien CB, Jia J, Zeldin G. Chronic hepatitis B genotype B or C E antigen positive patients: viral suppression, HBeAg loss and seroconversion rates are improved with telbivu-dine compared with lamivudine: results from a pooled analysis [abstract no. 255]. Gastroenterology 2008 Apr 1; 134 (4 Supp. 1): 760
64. Liaw Y-L, Wursthorn K, Thongsawat S, et al. Telbivudine-induced HBeAg seroconversion in chronic hepatitis B (CHB) is durable during 2 years off-treatment follow-up [abstract poster no. 1012]. 45th Annual Meeting of the European Association for the Study of the Liver (EASL); 2010 Apr 14-18; Vienna
65. Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety outcomes after 4 years of telbivudine treatment in patients with chronic hepatitis B (CHB) [abstract no. 482 plus poster]. 60th Annual Meeting of the American Association of the Study of Liver Diseases (AASLD); 2009 Oct 30-Nov 3; Boston (MA)
66. Safadi R, Xie Q, Chen Y, et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24 [abstract]. J Hepatol 2007; 46 Suppl. 1: 196-197
67. Dou X, Ding Y, Wang S, et al. Telbivudine suppressed HBV DNA and HBeAg simultaneously in HBeAg-positive chronic hepatitis B (CHB) patients, a two-center clinical study [abstract no. 499]. 60th Annual Meeting of the American Association of the Study of Liver Diseases: 2009 Oct 30-Nov 3; Boston (MA)
68. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. Epub 2010 Aug 19
69. Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48 (1): 22-26
70. Wursthorn K, Wedemeyer H, Manns MP, et al. Quantita-tion of serum HBeAg levels during prolonged telbivudine treatment and correlation with outcome [abstract plus poster no. 187]. 20th Asian Pacific Association for the Syudy of the Liver (APASL); 2010 Mar 25-28; Beijing
71. Chen W, Hou JL. Pharmacoeconomic evaluation of telbi-vudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B [in Chinese]. Zhonghua Ganzangbing Zazhi 2009 Aug; 17 (8): 569-573
72. Hu M, Chen W. Cost effectiveness of telbivudine vs. en-tecavir and lamivudine among patients with HBeAg-posi-tive chronic hepatitis B in China [abstract no. 1103]. 7th World Congress of the International Health Economics Association; 2009 Jul 12-15, Beijing
73. Tsoi KKF, Lui YYN, Wong VWS, et al. Cost-effectiveness analysis of antiviral treatment strategies based on the Roadmap Model in chronic hepatitis B virus (HBV) infection [abstract no. PE078]. Hepatol Int 2009; 3: 105
74. Lui YY, Tsoi KK, Wong VW, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antiviral Ther 2010 Jan; 15 (2): 145-155
75. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008; 26 (11): 937-949
76. National Institute for Health and Clinical Excellence. Tel-bivudine for the treatment of chronic hepatitis B [online]. Available from URL http://www.nice.org.uk/nicemedia/pdf/TA154Guidance.pdf [Accessed 2010 Mar 12]
77. Buti M, Brosa M, Casado MA, et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009 May 20; 51 (4): 640-646
78. Avila C, Goncalves J. Creatine kinase elevations during 4-years of continuous telbivudine treatment are transient and not predictive of uncommonly observed muscle-related symptoms [abstract no. 472 plus poster]. 60th Annual Meeting of the American Association of the Study of Liver Diseases; 2009 30 Oct-3 Nov; Boston (MA)
79. Laeufle R, Mayer H, Avila C. Assessment of the risk of peri-pheral neuropathy with telbivudine: analysis of the telbivu-dine global clinical safety database [abstract plus poster no. PP010]. 19th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2009 Feb 13-16; Hong Kong
80. Trylesinski A, O'Connor K, Kraev S, et al. Outcomes for newborns exposed to telbivudine during pregnancy: retrospective analysis of the Novartis safety and clinical databases [poster no. 189]. 20th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2010 Mar 25-28; Beijing
81. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, et al. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008 Mar; 8 (3): 167-178
82. Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133: 1458-1465
83. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algo-rithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastro-enterol Hepatol 2008 Dec; 6 (12): 1315-1341
84. Gane EJ. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int 2008 Sep; 2 (3): 304-307
85. Ahn S-H, Kweon Y-O, Paik S-W, et al. Telbivudine com-bination with adefovir versus adefovir monotherapy in HBeAg-positive chronic hepatitis B patients with lamivu-dine resistance [poster no. PP184]. 20th Asian Pacific Association for the Study of the Liver (APASL) Conference; 2010 Mar 25-28; Beijing